Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hepadnaviridae Infections

ClinicalTrials.gov lists 1,698 trials for Hepadnaviridae Infections or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 157.

MeSH D018347 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 177 Phase 1/2 Phase 1/2 44 Phase 2 Phase 2 241 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 245 Phase 4 Phase 4 333 Not applicable Not applicable 214 Observational Observational 423 Phase 1 Phase 1 177 Phase 1/2 Phase 1/2 44 Phase 2 Phase 2 241 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 245 Phase 4 Phase 4 333 Not applicable Not applicable 214 Observational Observational 423

Trials per phase (log scale)

1 more section with rows

2 of the 1,698 trials are tagged with Hepadnaviridae Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Hepadnaviridae Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hepadnaviridae Infections trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 85

1991: 1 trials (Observational 1) 1992: 3 trials (Observational 1, Phase 2 1, Phase 1 1) 1993: 2 trials (Phase 3 1, Phase 2 1) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 4 trials (Phase 4 1, Phase 3 2, Phase 2 1) 1997: 7 trials (Observational 2, Phase 3 3, Phase 2 2) 1998: 5 trials (Observational 1, Phase 2/3 1, Phase 2 3) 1999: 9 trials (Not applicable 1, Phase 3 6, Phase 2 1, Phase 1/2 1) 2000: 9 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 5) 2001: 13 trials (Observational 3, Phase 3 5, Phase 2 4, Phase 1 1) 2002: 20 trials (Observational 4, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 7) 2003: 35 trials (Other 1, Observational 3, Not applicable 2, Phase 4 8, Phase 3 12, Phase 2 7, Phase 1/2 2) 2004: 46 trials (Observational 6, Not applicable 3, Phase 4 8, Phase 3 19, Phase 2/3 1, Phase 2 6, Phase 1/2 2, Phase 1 1) 2005: 51 trials (Observational 10, Not applicable 6, Phase 4 11, Phase 3 14, Phase 2 8, Phase 1/2 1, Phase 1 1) 2006: 63 trials (Observational 5, Not applicable 5, Phase 4 11, Phase 3 32, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2007: 54 trials (Observational 7, Not applicable 3, Phase 4 20, Phase 3 15, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2008: 66 trials (Observational 12, Not applicable 7, Phase 4 25, Phase 3 17, Phase 2 4, Phase 1/2 1) 2009: 60 trials (Observational 14, Not applicable 9, Phase 4 22, Phase 3 1, Phase 2 6, Phase 1/2 3, Phase 1 5) 2010: 68 trials (Observational 20, Not applicable 4, Phase 4 15, Phase 3 14, Phase 2 12, Phase 1/2 1, Phase 1 2) 2011: 71 trials (Observational 23, Not applicable 8, Phase 4 17, Phase 3 16, Phase 2 3, Phase 1/2 1, Phase 1 3) 2012: 68 trials (Observational 21, Not applicable 5, Phase 4 14, Phase 3 14, Phase 2 5, Phase 1/2 3, Phase 1 6) 2013: 67 trials (Observational 19, Not applicable 8, Phase 4 23, Phase 3 9, Phase 2 3, Phase 1/2 2, Phase 1 3) 2014: 69 trials (Observational 21, Not applicable 15, Phase 4 13, Phase 3 8, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 5) 2015: 85 trials (Observational 15, Not applicable 8, Phase 4 31, Phase 3 4, Phase 2/3 1, Phase 2 12, Phase 1/2 2, Phase 1 12) 2016: 74 trials (Observational 20, Not applicable 13, Phase 4 18, Phase 3 8, Phase 2/3 2, Phase 2 6, Phase 1 7) 2017: 68 trials (Observational 21, Not applicable 10, Phase 4 15, Phase 3 5, Phase 2 7, Phase 1/2 2, Phase 1 8) 2018: 77 trials (Observational 17, Not applicable 13, Phase 4 16, Phase 3 2, Phase 2/3 3, Phase 2 10, Phase 1/2 4, Phase 1 12) 2019: 81 trials (Observational 19, Not applicable 17, Phase 4 14, Phase 3 2, Phase 2/3 2, Phase 2 15, Phase 1/2 1, Phase 1 11) 2020: 79 trials (Observational 19, Not applicable 11, Phase 4 7, Phase 3 4, Phase 2 19, Phase 1/2 2, Phase 1 17) 2021: 76 trials (Observational 22, Not applicable 9, Phase 4 10, Phase 3 3, Phase 2 16, Phase 1 16) 2022: 80 trials (Observational 26, Not applicable 11, Phase 4 7, Phase 3 2, Phase 2 16, Phase 1/2 2, Phase 1 16) 2023: 64 trials (Observational 19, Not applicable 7, Phase 4 4, Phase 3 1, Phase 2 13, Phase 1/2 4, Phase 1 16) 2024: 77 trials (Observational 26, Not applicable 13, Phase 4 5, Phase 3 1, Phase 2 12, Phase 1/2 3, Phase 1 17) 2025: 67 trials (Observational 24, Not applicable 10, Phase 4 4, Phase 3 7, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 52
2025 67
2024 77
2023 64
2022 80
2021 76
2020 79
2019 81
2018 77
2017 68

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 68 trials starting in 2026 and about 68 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 97 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 995 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hepadnaviridae Infections trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 177
Phase 1/2 44
Phase 2 241
Phase 2/3 17
Phase 3 245
Phase 4 333
Not applicable 214
Observational 423
Expanded access 4

How many Hepadnaviridae Infections trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 68
Recruiting 119
Enrolling by invitation 9
Active, not recruiting 54
Completed 920

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hepadnaviridae Infections trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 157
Hoffmann-La Roche 47
Gilead Sciences 44
Bristol-Myers Squibb 35
Sanofi Pasteur, a Sanofi Company 28

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Hepadnaviridae Infections? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Entecavir 152
GS-7340 73
PEGinterferon alfa-2a 68
LAMIVUDINE 45
Tenofovir 34

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
tenofovir disproxil fumarate 113
Engerix™ 67
telbivudine/LDT600 45
hepatitis B vaccines 37
adefovir dipivoxyl 31

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hepadnaviridae Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 222 55
Gastroenteritis 177 43
Bronchiolitis 117 19
Alanine aminotransferase increased 106 21
Hepatic neoplasm malignant 75 10

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hepadnaviridae Infections? (2)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrobial agents and chemotherapy 2013 Yes
Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. The Journal of general virology 2006 Yes

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages